Enliven Therapeutics, Inc. (ELVN) — Stock Score Summary

Enliven Therapeutics, Inc. (ELVN) has a MoatMap StockRank of 60/100 based on Quality (45/100), Value (37/100), and Momentum (63/100) factor scores. The current signal is HOLD. Enliven Therapeutics is a clinical-stage oncology biotech. As a pre-revenue company with binary clinical trial risks, it does not meet our Terry Smith quality criteria of high ROIC and established pricing power, nor does it align with our CDMO manufacturing theme.

Enliven Therapeutics, Inc. is a clinical-stage precision oncology company dedicated to discovering and developing highly selective and potent kinase inhibitors. The company's lead candidates target specific mutations in cancers such as chronic myeloid leukemia (CML) and solid tumors. Enliven's competitive advantage is its structure-guided drug design platform, enabling the development of best-in-class therapies with improved efficacy and safety profiles for targeted cancer treatment.

Key Financial Metrics

Price$36.11
Market Cap$2.5B
P/E (Forward)-14.85
Price/Book4.77
Return on Equity-26.6%
Return on Invested Capital-26.0%
Debt/Equity0.07
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-46M

Enliven Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Enliven Therapeutics, Inc.’s (ELVN) StockRank?
MoatMap’s StockRank for Enliven Therapeutics, Inc. (ELVN) is 60/100, with a Hold signal. It is a composite of Quality (45), Value (37), and Momentum (63) factor ranks across MoatMap’s 19,000+ stock universe.
Does Enliven Therapeutics, Inc. have an economic moat?
Enliven Therapeutics, Inc. (ELVN) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Enliven Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Enliven Therapeutics, Inc. (ELVN) is Hold, based on a StockRank of 60/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Enliven Therapeutics, Inc. in?
Enliven Therapeutics, Inc. (ELVN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksELVN deep dive reportAI ChampionsHow we score stocksSense-check another stock